Search
Bortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigational[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. … [L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Abormib 1 mg-Pulver zur Herstellung einer Injektionslösung, Abormib 2,5 mg-Pulver zur Herstellung einer InjektionslösungBevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigationalvials formulated for intravenous oncology use. … [A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target.
Categories: Experimental Unapproved Treatments for COVID-19, VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsProducts: ZIRABEV CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/4 ML, ZIRABEV CONCENTRATE FOR SOLUTION FOR INFUSION 400 MG/16 MLClonidine
go.drugbank.com/drugs/DB00575ApprovedInvestigationalClonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.
Categories: Antihypertensive Agents Indicated for Hypertension, Cytochrome P-450 SubstratesProducts: Mar-clonidineAlbuterol
go.drugbank.com/drugs/DB01001ApprovedInvestigationalVet approvedThe R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. … It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart.
Mixtures: COMBIVENT UNIT DOSE VIAL FOR INHALATION, Combivent Lösung für einen Vernebler in EinzeldosisbehältnissenCategories: Drugs for Obstructive Airway Diseases, Cytochrome P-450 CYP3A InhibitorsSemzuvolimab
go.drugbank.com/drugs/DB18920InvestigationalSemzuvolimab is under investigation in clinical trial NCT03149211 (To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults).
Synonyms: DB4C7 mAb, Mab db4c7TPIV 200
go.drugbank.com/drugs/DB17318InvestigationalTPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage colony-stimulating factor (GM-CSF).
Synonyms: TPIV200/huFR-1Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Categories: HER2 Receptor Antagonists, Receptor, ErbB-2, antagonists & inhibitorsProducts: Perjeta 420 mg concentrate for solution for infusion, PERJETA CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/14MLOndansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawn[L5221] The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation. … A competitive serotonin type 3 receptor antagonist.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Mar-ondansetron, Mar-ondansetron ODTChAd-triCoV/Mac
go.drugbank.com/drugs/DB24997InvestigationalChAd-triCoV/Mac is a biologic drug. ChAd-triCoV/Mac is under investigation in clinical trial NCT06381739 (A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol).
Synonyms: ChAd-triCoV/MacUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigational[A187349] It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. … In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.
Categories: Biologics for psoriasis treatmentProducts: STELARA CONCENTRATE FOR SOLUTION FOR INFUSION 130MG/26ML, STELARA 130mg/26mL Concentrate for Solution for Infusion